New multiplexed flow cytometric assay to measure anti‐peptide antibody: a novel tool for monitoring immune responses to peptides used for immunization
- 1 October 2004
- journal article
- research article
- Published by Taylor & Francis in Scandinavian Journal of Clinical and Laboratory Investigation
- Vol. 64 (6) , 535-546
- https://doi.org/10.1080/00365510410007008
Abstract
Peptide-based vaccination has a great potential for the prevention and treatment of various diseases. There is, however, no appropriate monitoring system to measure immune responses to vaccinated peptides, which hampers the development of therapeutically effective vaccine regimens to various diseases. In this study a new multiplexed flow cytometric assay using the Luminex system to monitor humoral immune responses to vaccinated peptides is described. Although the sensitivity is mostly equal to that of the traditional enzyme-linked immunosorbent assay (ELISA), the new assay has several advantages over ELISA in that it minimizes the amount of sera needed, running costs and working periods, and thus will be a novel tool for monitoring immune responses to vaccinated peptides.Keywords
This publication has 15 references indexed in Scilit:
- Humoral Responses to Peptides Correlate with Overall Survival in Advanced Cancer Patients Vaccinated with Peptides Based on Pre-existing, Peptide-Specific Cellular ResponsesClinical Cancer Research, 2004
- Induction of cellular and humoral immune responses to tumor cells and peptides in HLA‐A24 positive hormone‐refractory prostate cancer patients by peptide vaccinationThe Prostate, 2003
- A simple culture protocol to detect peptide-specific cytotoxic T lymphocyte precursors in the circulationCancer Immunology, Immunotherapy, 2002
- Measurement of interferon-γ by high-throughput fluorometric microvolume assay technology systemJournal of Immunological Methods, 2002
- Perspectives: towards a peptide-based vaccine against hepatitis C virusMolecular Immunology, 2001
- Intron loss in the SART1 genes of Fugu rubripes and Tetraodon nigroviridisGene, 2001
- Induction of primary NY-ESO-1 immunity: CD8+ T lymphocyte and antibody responses in peptide-vaccinated patients with NY-ESO-1+ cancersProceedings of the National Academy of Sciences, 2000
- Tumor regressions observed in patients with metastatic melanoma treated with an antigenic peptide encoded by geneMAGE-3 and presented by HLA-A1International Journal of Cancer, 1999
- Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanomaNature Medicine, 1998
- A Gene Encoding an Antigen Recognized by Cytolytic T Lymphocytes on a Human MelanomaScience, 1991